Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441096 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women
A NA study, sponsored by SF Research Institute.
- Not yet
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT07441096 is a NA study that has not yet begun recruiting, run by SF Research Institute. The registered enrollment target is 60 participants.
The verdict
NCT07441096, a NA study, has not yet begun recruiting, sponsored by SF Research Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
Premenstrual syndrome (PMS) is a common condition that affects women of reproductive age and is associated with emotional, physical, and behavioral symptoms such as mood swings, irritability, stress, sleep problems, fatigue, and abdominal discomfort. These symptoms typically occur during the days leading up to menstruation and may interfere with daily activities and overall quality of life. This study is designed to evaluate the efficacy and safety of Shatavari (Asparagus racemosus) root extract compared with placebo in women with mild to moderate PMS. Eligible participants will be randomly assigned to receive either Shatavari root extract (300 mg) or an identical placebo capsule once daily for 12 weeks. The study will assess changes in PMS symptoms, stress levels, sleep quality, and quality of life using validated questionnaires, along with measurements of salivary cortisol. Safety will be evaluated through clinical laboratory tests and monitoring of adverse events throughout the study.
Interventions
- OTHER Placebo Capsule
- DIETARY_SUPPLEMENT Shatavari Root Extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2026-07-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07441096
The ClinicalTrials.gov registry entry for NCT07441096 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SF Research Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Capsule is the first listed.
NCT07441096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07441096 about?
NCT07441096 is a clinical study titled "Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women". Premenstrual syndrome (PMS) is a common condition that affects women of reproductive age and is associated with emotional, physical, and behavioral symptoms such as mood swings, irritability, stress, sleep problems, fatigue, and abdominal discomfort. These symptoms typically occur during the days le...
What is the current status of trial NCT07441096?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2026-03-20. Estimated completion is 2026-07-08.
What interventions are being tested in trial NCT07441096?
The interventions under investigation include: Placebo Capsule (OTHER), Shatavari Root Extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07441096?
This trial is sponsored by SF Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.